Merck’s targeted lung cancer drug tepotinib wins early access in UKThe UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small Share XMerck’s targeted lung cancer drug tepotinib wins early access in UKhttps://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/
Merck makes another bioelectronics play, partnering with InnerviaMerck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia Share XMerck makes another bioelectronics play, partnering with Innerviahttps://pharmaphorum.com/news/merck-makes-another-bioelectronics-play-partnering-innervia/
Merck partners neuroloop on bioelectronic device for inflammationMerck KGaA has joined forces with a unit of medtech firm B Braun – neuroloop – on a Share XMerck partners neuroloop on bioelectronic device for inflammationhttps://pharmaphorum.com/news/merck-partners-neuroloop-on-bioelectronic-device-for-inflammation/
Inside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimabSwiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory Share XInside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimabhttps://pharmaphorum.com/views-and-analysis/inside-moonlakes-raid-on-merck-kgaas-inflammatory-disease-hopeful-sonelokimab/
NICE says no to Merck Serono’s Bavencio in bladder cancerMerck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer Share XNICE says no to Merck Serono’s Bavencio in bladder cancerhttps://pharmaphorum.com/news/nice-says-no-to-merck-seronos-bavencio-in-bladder-cancer/
MoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabThere’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a Share XMoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabhttps://pharmaphorum.com/news/moonlake-launches-licensing-in-merck-kgaas-cosentyx-challenger-sonelokimab/
Avillion/Merck psoriasis nanobody hits the mark in phase 2UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Share XAvillion/Merck psoriasis nanobody hits the mark in phase 2https://pharmaphorum.com/news/avillion-merck-psoriasis-nanobody-hits-the-mark-in-phase-2/
GSK’s big-ticket cancer alliance with Merck KGaA stumbles againMerck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a Share XGSK’s big-ticket cancer alliance with Merck KGaA stumbles againhttps://pharmaphorum.com/news/gsks-big-ticket-cancer-alliance-with-merck-kgaa-hits-another-hurdle/
Merck KGaA offloads failed MEK programme to startup Day OneUS biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s Share XMerck KGaA offloads failed MEK programme to startup Day Onehttps://pharmaphorum.com/news/merck-kgaa-offloads-failed-mek-programme-to-startup-day-one/
